Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OCL022
MIFTS: 55

Ocular Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Ocular Melanoma

About this section

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 12 77 54 56 15 17
Intraocular Melanoma 12 54 30 6
Malignant Melanoma of Eye 74
Melanoma of the Uvea 54
Melanoma of Eye 12
Uveal Melanoma 54
Eye Melanoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Eye diseases Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1752
UMLS 74 C0558356
Sources

Summaries for Ocular Melanoma

About this section
NIH Rare Diseases : 54 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors. 

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to tumor predisposition syndrome and melanoma. An important gene associated with Ocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are Human cytomegalovirus infection and Ras signaling pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : 77 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Sources

Related Diseases for Ocular Melanoma

About this section

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 tumor predisposition syndrome 32.8 BAP1 BRCA2
2 melanoma 31.0 CDKN2A MAGEA1 MAGEA3 MC1R NRAS
3 macular dystrophy, dominant cystoid 30.0 SERPINF1 VEGFA
4 malignant peritoneal mesothelioma 30.0 BAP1 CDKN2A
5 dysplastic nevus syndrome 29.9 BRCA2 CDKN2A
6 malignant conjunctival melanoma 29.4 GNA11 GNAQ NRAS
7 melanoma, uveal 28.5 BAP1 CDKN2A GNA11 GNAQ MAGEA1 MC1R
8 melanoma, cutaneous malignant 1 28.3 BAP1 CDKN2A GNA11 GNAQ KIT MC1R
9 posterior uveal melanoma 12.5
10 necrotic uveal melanoma 12.4
11 mixed cell uveal melanoma 12.3
12 spindle cell intraocular melanoma 12.3
13 uveal epithelioid cell melanoma 11.4
14 bap1 tumor predisposition syndrome 11.4
15 iris spindle cell melanoma 11.2
16 maxillary sinus adenoid cystic carcinoma 10.4 IL2 KIT
17 macular retinal edema 10.3
18 ovarian melanoma 10.3 KIT NRAS
19 conventional fibrosarcoma 10.3 KIT NRAS
20 malignant spindle cell melanoma 10.3 KIT NRAS
21 adenoid basal cell carcinoma 10.2 CDKN2A KIT
22 neovascular glaucoma 10.2
23 myotonic dystrophy 10.2
24 myotonia atrophica 10.2
25 peritoneum cancer 10.2 BAP1 BRCA2
26 lymphoepithelioma-like thymic carcinoma 10.2 CDKN2A KIT
27 glycogen-rich clear cell breast carcinoma 10.2 BRCA2 CDKN2A
28 depression 10.2
29 skin melanoma 10.2
30 balanoposthitis 10.2 CDKN2A IL2
31 breast giant fibroadenoma 10.2 BRCA2 CDKN2A
32 infiltrating angiolipoma 10.2 CDKN2A VEGFA
33 anxiety 10.1
34 herpes simplex 10.1
35 hypoxia 10.1
36 cervicitis 10.1 CDKN2A IL2
37 balanitis xerotica obliterans 10.1 CDKN2A VEGFA
38 acral lentiginous melanoma 10.1 CDKN2A KIT NRAS
39 melanoma metastasis 10.1
40 insulin-like growth factor i 10.0
41 hemangioma 10.0
42 uveitis 10.0
43 optic nerve disease 10.0
44 neuropathy 10.0
45 female reproductive system disease 10.0 BRCA2 CDKN2A VEGFA
46 reproductive system disease 10.0 BRCA2 CDKN2A VEGFA
47 melanocytic nevus syndrome, congenital 10.0 MC1R NRAS
48 pharynx cancer 10.0 CDKN2A KIT VEGFA
49 endocrine gland cancer 10.0 BRCA2 CDKN2A VEGFA
50 gastrointestinal system cancer 10.0 CDKN2A KIT VEGFA

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma
Sources

Symptoms & Phenotypes for Ocular Melanoma

About this section

MGI Mouse Phenotypes related to Ocular Melanoma:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.29 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
2 endocrine/exocrine gland MP:0005379 10.28 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
3 immune system MP:0005387 10.26 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
4 behavior/neurological MP:0005386 10.23 BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
5 cardiovascular system MP:0005385 10.22 BAP1 CDKN2A GNA11 GNAQ IL2 KIT
6 growth/size/body region MP:0005378 10.22 BAP1 BRCA2 CDKN2A GNA11 GNAQ IL2
7 homeostasis/metabolism MP:0005376 10.19 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
8 digestive/alimentary MP:0005381 10.15 BAP1 BRCA2 CDKN2A IL2 KIT NRAS
9 integument MP:0010771 10.11 BAP1 BRCA2 CDKN2A GNA11 GNAQ KIT
10 craniofacial MP:0005382 10.03 GNA11 GNAQ KIT MC1R NRAS VEGFA
11 limbs/digits/tail MP:0005371 9.98 BRCA2 GNA11 GNAQ KIT MC1R NRAS
12 neoplasm MP:0002006 9.97 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
13 liver/biliary system MP:0005370 9.88 CDKN2A GNA11 IL2 KIT NRAS VEGFA
14 no phenotypic analysis MP:0003012 9.87 BAP1 CDKN2A IL2 KIT MC1R NRAS
15 normal MP:0002873 9.86 BRCA2 CIITA GNA11 GNAQ KIT NRAS
16 pigmentation MP:0001186 9.7 CDKN2A GNA11 GNAQ KIT MC1R NRAS
17 respiratory system MP:0005388 9.5 BAP1 CDKN2A GNA11 GNAQ IL2 KIT
18 skeleton MP:0005390 9.28 BRCA2 CDKN2A CIITA GNA11 GNAQ KIT
Sources

Drugs & Therapeutics for Ocular Melanoma

About this section

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
6 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
7 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
8 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
16
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
17
Melphalan Approved Phase 3,Phase 2 148-82-3 460612 4053
18
Fotemustine Experimental, Investigational Phase 3
19 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
24 Mitogens Phase 3,Phase 2,Phase 1
25 Endothelial Growth Factors Phase 3,Phase 2
26
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
Sodium Citrate Approved, Investigational Phase 2 68-04-2
29
Cisplatin Approved Phase 2,Phase 1 15663-27-1 441203 84093 2767
30
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
31
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
32
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
33
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
34
Lenalidomide Approved Phase 2 191732-72-6 216326
35
Ipilimumab Approved Phase 2,Phase 1,Early Phase 1 477202-00-9
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Carboplatin Approved Phase 2,Phase 1 41575-94-4 38904 10339178 498142
38
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
39
Sirolimus Approved, Investigational Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
40
Everolimus Approved Phase 2,Not Applicable 159351-69-6 6442177 70789204
41
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Pasireotide Approved Phase 2 396091-73-9 9941444
44
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
45 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
46
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
47
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
48
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
49
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
50
Aluminum sulfate Approved Phase 2 10043-01-3

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
4 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
5 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
6 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
7 Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
8 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
9 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
10 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
11 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
12 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
13 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
14 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
15 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
16 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
17 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Unknown status NCT02936388 Phase 2
18 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
19 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
20 STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
21 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
22 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
23 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
24 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
25 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
26 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
27 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
28 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
29 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
30 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
31 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
32 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
33 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
34 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
35 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
36 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
37 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
38 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
39 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
40 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2 GM-CSF
41 Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003339 Phase 2
42 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
43 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
44 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
45 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
46 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
47 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
48 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
49 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
50 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant

Search NIH Clinical Center for Ocular Melanoma

Sources

Genetic Tests for Ocular Melanoma

About this section

Genetic tests related to Ocular Melanoma:

# Genetic test Affiliating Genes
1 Intraocular Melanoma 30
Sources

Anatomical Context for Ocular Melanoma

About this section

MalaCards organs/tissues related to Ocular Melanoma:

42
Eye, Liver, Retina, Testes, Bone, Lung, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

20
The Eye
Sources

Publications for Ocular Melanoma

About this section

Articles related to Ocular Melanoma:

(show top 50) (show all 350)
# Title Authors Year
1
Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. ( 30797699 )
2019
2
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. ( 30767147 )
2019
3
Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanoma? ( 30566923 )
2019
4
Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )
2018
5
Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: inA vitro study. ( 29707895 )
2018
6
Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )
2018
7
Headache with Aura: A case report of ocular melanoma. ( 30135025 )
2018
8
Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. ( 30671022 )
2018
9
The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation. ( 30320098 )
2018
10
Is Collaborative Ocular Melanoma Study (COMS) still relevant? ( 30249817 )
2018
11
Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases. ( 30134646 )
2018
12
Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )
2017
13
Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )
2017
14
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
15
PRL-3/PTP4A3 phosphatase regulates integrin I^1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )
2017
16
Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )
2017
17
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )
2017
18
The toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
19
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
20
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
21
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
22
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
23
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2016
24
Metastatic melanoma after 23a88years of primary ocular melanoma. ( 27881589 )
2016
25
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
26
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
27
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
28
Metastatic Ocular Melanoma to the Liver Exhibits Infiltrative and Nodular Growth Patterns. ( 27476775 )
2016
29
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
30
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
31
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
32
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
33
A challenging case of ocular melanoma. ( 26429178 )
2015
34
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
35
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
36
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
37
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
38
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
39
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
40
Isolated Hepatic Perfusion for Ocular Melanoma Metastasis: Registry Data Suggests a Survival Benefit. ( 24141377 )
2013
41
Combined surgical resection and radiofrequency ablation as treatment for metastatic ocular melanoma. ( 22766897 )
2013
42
Pretherapeutic laboratory findings, extent of metastasis and choice of treatment as prognostic markers in ocular melanoma- a single centre experience. ( 23057648 )
2013
43
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
44
Ocular melanoma: an overview of the current status. ( 23826405 )
2013
45
Ocular melanoma metastasizing to intra-abdominal lymph nodes. ( 23762736 )
2013
46
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013
47
Solitary secondary malignant melanoma of clavicle two years after enuclation for ocular melanoma. ( 23424696 )
2013
48
Diffusion-weighted imaging of ocular melanoma. ( 23614974 )
2013
49
Left ventricular metastasis from ocular melanoma: a new, rare, and unusual pathway? ( 23816109 )
2013
50
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. ( 23799844 )
2013
Sources

Variations for Ocular Melanoma

About this section

ClinVar genetic disease variations for Ocular Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
2 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
3 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
4 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
5 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
6 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
7 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
8 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
9 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh37 Chromosome 9, 80409488: 80409489
10 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh38 Chromosome 9, 77794572: 77794573
Sources

Expression for Ocular Melanoma

About this section
Search GEO for disease gene expression data for Ocular Melanoma.
Sources

Pathways for Ocular Melanoma

About this section

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Human cytomegalovirus infection 38
Show member pathways
 12.67 CDKN2A GNA11 GNAQ NRAS VEGFA
2
Ras signaling pathway 38
Show member pathways
 12.48 GNAQ KIT NRAS VEGFA
3
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.41 GNA11 GNAQ NRAS VEGFA
4
Endometrial cancer 38
Show member pathways
 12.4 BRCA2 CDKN2A KIT NRAS VEGFA
5
NF-kappaB Signaling 4
12.25 CIITA IL2 KIT MAGEA3
6
Pathways in cancer 38
11.95 BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
7
UVA-Induced MAPK Signaling 65
Show member pathways
 11.78 GNA11 GNAQ NRAS
8
S1P3 pathway 1
Show member pathways
 11.69 GNA11 GNAQ VEGFA
9
Corticotropin-releasing hormone signaling pathway 1
11.51 GNA11 GNAQ IL2
10
G-protein signaling_RhoA regulation pathway 23
11.4 GNA11 GNAQ IL2 NRAS
11
Bladder cancer 38 1
11.2 CDKN2A NRAS VEGFA
12
Transcription_Transcription factor Tubby signaling pathways 23
10.91 GNA11 GNAQ NRAS
13
Long-term depression 38
10.91 GNA11 GNAQ NRAS
14
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.8 GNAQ NRAS
Sources

GO Terms for Ocular Melanoma

About this section

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 action potential GO:0001508 9.46 GNA11 GNAQ
2 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.43 GNA11 GNAQ
3 developmental pigmentation GO:0048066 9.4 GNA11 KIT
4 somatic stem cell division GO:0048103 9.37 CDKN2A KIT
5 phototransduction, visible light GO:0007603 9.32 GNA11 GNAQ
6 entrainment of circadian clock GO:0009649 9.26 GNA11 GNAQ
7 positive regulation of protein kinase C signaling GO:0090037 9.16 MC1R VEGFA
8 positive regulation of endothelial cell proliferation GO:0001938 9.13 NRAS PDCD6 VEGFA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.8 IL2 KIT VEGFA

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 BAP1 BRCA2 CDKN2A CIITA GNAQ IL2
2 GTP binding GO:0005525 9.56 CIITA GNA11 GNAQ NRAS
3 G-protein beta/gamma-subunit complex binding GO:0031683 9.32 GNA11 GNAQ
4 guanyl nucleotide binding GO:0019001 9.16 GNA11 GNAQ
5 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ
Sources

Sources for Ocular Melanoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....